Physician treatment preferences in rheumatoid arthritis of differing disease severity and activity: The impact of cost on first‐line therapy

Abstract

Pharmacoeconomics appear to play a dominant role in rheumatologists' choice of treatment regimens, at times contrary to the physician's perception of the effectiveness of a drug. Future studies should address physician preferences in more depth with respect to cost and its various components.